Ibex Technologies (TSXV:IBT) Cash, Cash Equivalents, Marketable Securities : C$8.69 Mil (As of Jan. 2024)

View and export this data going back to 1986. Start your Free Trial

What is Ibex Technologies Cash, Cash Equivalents, Marketable Securities?

Ibex Technologies's quarterly cash, cash equivalents, marketable securities increased from Jul. 2023 (C$8.55 Mil) to Oct. 2023 (C$8.75 Mil) but then stayed the same from Oct. 2023 (C$8.75 Mil) to Jan. 2024 (C$8.69 Mil).

Ibex Technologies's annual cash, cash equivalents, marketable securities increased from Jul. 2021 (C$4.43 Mil) to Jul. 2022 (C$7.64 Mil) and increased from Jul. 2022 (C$7.64 Mil) to Jul. 2023 (C$8.55 Mil).

Ibex Technologies Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Ibex Technologies's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ibex Technologies Cash, Cash Equivalents, Marketable Securities Chart

Ibex Technologies Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

2.58

3.71

4.43

7.64

8.55

Ibex Technologies Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															7.49	7.52	8.55	8.75	8.69

Ibex Technologies Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Ibex Technologies (TSXV:IBT) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Ibex Technologies Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Ibex Technologies's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ibex Technologies (TSXV:IBT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ibex Technologies Inc (TSXV:IBT) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

IBXNF:USA IBT:Germany

Address

5485 Pare Street, Suite 100, Montreal, QC, CAN, H4P 1P7

Website

https://www.ibex.ca

Ibex Technologies Inc is a company engaged in the production and sale of diagnostic products. It manufactures and markets enzymes for biomedical use, through its subsidiaries. It also manufactures and markets a series of arthritis assays that have applications in osteoarthritis research. It sells two product lines namely, Enzymes for in-vitro diagnostics and research, and Tests for osteoarthritis research. The group provides services like Filing and lyophilization of disposable diagnostic components, and Custom fermentation and purification of enzymes for diagnostic companies. Geographically, the firm sells its products in Canada, Germany, the U.S., the U.K., and other countries of which the majority of the revenue is generated from the U.S.

Ibex Technologies (TSXV:IBT) Headlines

No Headlines